-
Medical journals
- Career
Talc - Standard Medicament in the Treatment of Malignant Pleural Effusion
Authors: M. Bednář; P. Bezdíček 1
Authors‘ workplace: Ústav lékařské mikrobiologie 3. LF UK a FNKV, Praha, 1 Division of Pulmonary and Critical Care Medicine, The New York Hospital - Cornell University Medical College, New York, USA
Published in: Čas. Lék. čes. 1999; : 82-84
Category:
Overview
Currently, talc is the most effective and widely-used agent for chemical pleurodesis in the treatment of bothmalignant pleural effusion and pneumothorax. Its popularity has been growing due to the low incidence of sideeffects, low cost and higher success rate in comparison with other agents (tetracyclines, bleomycin, Corynebacteriumparvum). The guidelines for talc pleurodesis are summarized and the history of the Corynebacterium parvum as anagent for chemical pleurodesis is mentioned. Its production in the Czech Republic has been halted due to the increasedinterest in the talc as a chemical sclerosant.
Key words:
malignant effusion, pneumothorax, pleurodesis, talc, Corynebacterium parvum, tetracyclin, bleomy-cin.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental Hygienist
Article was published inJournal of Czech Physicians
-
All articles in this issue
- Health Needs Assessment. Part 2. Need for Health and Need for Health Care
- Endocrinology 1999–2000
- Genetic Predisposition for Multiple Metabolic Syndrome. Part. 2. Candidate Genes for TypeII Diabetes Mellitus
- Skin Explant Assay – an in vitro Graft versus Host Disease PredictiveTest for Allogeneic Haematopoietic Stem Cell Transplantation
- Molecular Genetic Analysis of Alzheimer’s Disease in the Czech Population.Mutation (APP-717) in the Gene for the Amyloid Precursor Protein (APP)
- Budesonide (Turbuhaler), 400 mg/day, is at Least as Effective as a DoubleDose of Beclomethasone (MDI) in Patients with Mild to Medium Severe Bronchial Asthma
- Common Polymorphisms in the Cholesterol Ester Transfer Protein,Apolipoprotein CIII and Lipoprotein Lipase Genes in High- and Low-Cholesterolemic Children
- Prevention of Bacterial Endocarditis in Patients with Prosthetic Valve
- Talc - Standard Medicament in the Treatment of Malignant Pleural Effusion
- Return of Czech Health Professionals to Most in Spring 1945
- On the Use of Publications and Documents of WHO
- Development of European Medicine up to Vesalius (16th century)
- Effects of Hormonal Replacement Therapy on the Cardiovascular System
- Journal of Czech Physicians
- Journal archive
- Current issue
- Online only
- About the journal
Most read in this issue- Talc - Standard Medicament in the Treatment of Malignant Pleural Effusion
- Budesonide (Turbuhaler), 400 mg/day, is at Least as Effective as a DoubleDose of Beclomethasone (MDI) in Patients with Mild to Medium Severe Bronchial Asthma
- Health Needs Assessment. Part 2. Need for Health and Need for Health Care
- Development of European Medicine up to Vesalius (16th century)
Login#ADS_BOTTOM_SCRIPTS#Forgotten passwordEnter the email address that you registered with. We will send you instructions on how to set a new password.
- Career